RadisMed is a biomedical company developing orphan drugs for highly profitable markets with severe unmet medical needs.
RadisMed is a biomed start-up that develops drugs for the treatment of rare diseases with severe unmet medical needs. During its first business stage, the company is focused on cardiovascular diseases with high market potential.
RadisMed has acquired a technology from the University of San Diego and has established a solid network of industry collaborators. It is raising its first round of private investment to leverage with public funds.